Barriers to conducting deprescribing in the elderly population amid the COVID-19 pandemic

Deprescribing aims to reduce polypharmacy, especially in the elderly population, in order to maintain or improve quality of life, reduce harm from medications, and limit healthcare expenditure. Coronavirus disease (COVID-19) is an infectious disease that has led to a pandemic and has changed the liv...

Full description

Saved in:
Bibliographic Details
Published inResearch in social and administrative pharmacy Vol. 17; no. 1; pp. 1942 - 1945
Main Authors Elbeddini, Ali, Prabaharan, Thulasika, Almasalkhi, Sarah, Tran, Cindy, Zhou, Yueyang
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.01.2021
Published by Elsevier Inc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Deprescribing aims to reduce polypharmacy, especially in the elderly population, in order to maintain or improve quality of life, reduce harm from medications, and limit healthcare expenditure. Coronavirus disease (COVID-19) is an infectious disease that has led to a pandemic and has changed the lives many throughout the world. The mode of transmission of this virus is from person to person through the transfer of respiratory droplets. Therefore, non-essential healthcare services involving direct patient interactions, including deprescribing, has been on hiatus to reduce spread. Barriers to deprescribing before the pandemic include patient and system related factors, such as resistance to change, patient's knowledge deficit about deprescribing, lack of alternatives for treatment of disease, uncoordinated delivery of health services, prescriber's attitudes and/or experience, limited availability of guidelines for deprescribing, and lack of evidence on preventative therapy. Some of these barriers can be mitigated by using the following interventions:patient education, prioritization of non-pharmacological therapy, incorporation of electronic health record (EHR), continuous prescriber education, and development of research studies on deprescribing. Currently, deprescribing cannot be delivered through in person interactions, so virtual care is a reasonable alternative format. The full incorporation of EHR throughout Canada can add to the success of this strategy. However, there are several challenges of conducting deprescribing virtually in the elderly population. These challenges include, but are not limited, to their inability to use technology, lack of literacy, lack of assistance from others, greater propensity for withdrawal effects, and increased risk of severe consequences, if hospitalized. Virtual care is the future of healthcare and in order to retain the benefits of deprescribing, additional initiatives should be in place to address the challenges that elderly patients may experience in accessing deprescribing virtually. These initiatives should involve teaching elderly patients how to use technology to access health services and with technical support in place to address any concerns.
AbstractList Deprescribing aims to reduce polypharmacy, especially in the elderly population, in order to maintain or improve quality of life, reduce harm from medications, and limit healthcare expenditure. Coronavirus disease (COVID-19) is an infectious disease that has led to a pandemic and has changed the lives many throughout the world. The mode of transmission of this virus is from person to person through the transfer of respiratory droplets. Therefore, non-essential healthcare services involving direct patient interactions, including deprescribing, has been on hiatus to reduce spread. Barriers to deprescribing before the pandemic include patient and system related factors, such as resistance to change, patient's knowledge deficit about deprescribing, lack of alternatives for treatment of disease, uncoordinated delivery of health services, prescriber's attitudes and/or experience, limited availability of guidelines for deprescribing, and lack of evidence on preventative therapy. Some of these barriers can be mitigated by using the following interventions:patient education, prioritization of non-pharmacological therapy, incorporation of electronic health record (EHR), continuous prescriber education, and development of research studies on deprescribing. Currently, deprescribing cannot be delivered through in person interactions, so virtual care is a reasonable alternative format. The full incorporation of EHR throughout Canada can add to the success of this strategy. However, there are several challenges of conducting deprescribing virtually in the elderly population. These challenges include, but are not limited, to their inability to use technology, lack of literacy, lack of assistance from others, greater propensity for withdrawal effects, and increased risk of severe consequences, if hospitalized. Virtual care is the future of healthcare and in order to retain the benefits of deprescribing, additional initiatives should be in place to address the challenges that elderly patients may experience in accessing deprescribing virtually. These initiatives should involve teaching elderly patients how to use technology to access health services and with technical support in place to address any concerns.
Author Tran, Cindy
Prabaharan, Thulasika
Almasalkhi, Sarah
Zhou, Yueyang
Elbeddini, Ali
Author_xml – sequence: 1
  givenname: Ali
  surname: Elbeddini
  fullname: Elbeddini, Ali
  email: aelbeddini@wdmh.on.ca
  organization: Winchester District Memorial Hospital, 566 Louise Street, Winchester, ON, KK0C2K0, Canada
– sequence: 2
  givenname: Thulasika
  surname: Prabaharan
  fullname: Prabaharan, Thulasika
  email: thulasika.prabaharan@mail.utoronto.ca
  organization: Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College St, Toronto, M5S 3M2, Canada
– sequence: 3
  givenname: Sarah
  surname: Almasalkhi
  fullname: Almasalkhi, Sarah
  email: sarah.almasalkhi@mail.utoronto.ca
  organization: Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College St, Toronto, M5S 3M2, Canada
– sequence: 4
  givenname: Cindy
  surname: Tran
  fullname: Tran, Cindy
  email: cindy.tran@mail.utoronto.ca
  organization: Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College St, Toronto, M5S 3M2, Canada
– sequence: 5
  givenname: Yueyang
  surname: Zhou
  fullname: Zhou, Yueyang
  email: Yzhou@uottawa.ca
  organization: Faculty of Science, University of Ottawa, 75 Laurier Ave. East, Ottawa, ON, K1N 6N5, Canada
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32499161$$D View this record in MEDLINE/PubMed
BookMark eNqFkN1KxDAQhYMo_j-C0hdozSRNu71RdP2Fhb1RwauQJlM3S5uUpCv49nZdFb3yamaYOecw3wHZdt4hISdAM6BQnC2zqPqFCl3GKKMZFRllYovsQ8XzdAKCbo-9EJCWOcAeOYhxSSkvKeS7ZI-zvKqggH3ycqVCsBhiMvhEe2dWerDuNTHYB4w62Ho9WZcMC0ywNRja96T3_apVg_UuUZ01n7vp_PnhOoUq6ZUz2Fl9RHYa1UY8_qqH5On25nF6n87mdw_Ty1mq86Ic0hrKquDAtW4KXjWUa5gUiCwXrMaK5ZpzoZAygxpoMeGqVkznAkrD64phww_J-ca3X9UdGo1uCKqVfbCdCu_SKyv_bpxdyFf_JksmCsFgNBAbAx18jAGbHy1QuWYtl_KLtVyzllTIkfWoO_0d_KP6hjseXGwOcHz_bYQso7boNBobUA_SePtPxAc-3ZZD
CitedBy_id crossref_primary_10_1111_bcpt_13886
crossref_primary_10_1177_17151635221114114
crossref_primary_10_2196_52031
crossref_primary_10_1016_j_bbih_2021_100353
crossref_primary_10_1186_s12911_023_02194_4
crossref_primary_10_1111_jgs_18047
crossref_primary_10_7748_nop_2023_e1449
crossref_primary_10_1089_cyber_2023_0571
crossref_primary_10_3390_ijerph18041755
crossref_primary_10_1016_j_heliyon_2024_e25197
crossref_primary_10_3390_ph15080977
crossref_primary_10_7748_nop_2023_e1441
crossref_primary_10_1016_j_ifacol_2021_10_529
crossref_primary_10_1007_s40266_023_01016_6
crossref_primary_10_53886_gga_e0210059
crossref_primary_10_1007_s40266_024_01110_3
crossref_primary_10_1177_14604582221075561
Cites_doi 10.1016/j.jaut.2020.102433
10.1016/j.sapharm.2019.07.004
10.1016/j.sapharm.2015.12.004
10.7812/TPP/17-157
10.1186/s12875-019-0953-4
10.1002/hsr2.45
10.1016/j.jamda.2019.08.031
10.1016/j.sapharm.2018.08.012
10.1111/jcpt.12688
10.1016/j.sapharm.2020.03.003
10.1016/j.sapharm.2018.08.014
10.1016/j.sapharm.2017.01.003
10.1016/j.sapharm.2016.08.006
10.1016/j.maturitas.2020.01.009
10.3906/sag-2004-172
10.1016/j.sapharm.2020.04.029
ContentType Journal Article
Copyright 2020
Crown Copyright © 2020. Published by Elsevier Inc. All rights reserved.
Crown Copyright © 2020 Published by Elsevier Inc. All rights reserved. 2020
Copyright_xml – notice: 2020
– notice: Crown Copyright © 2020. Published by Elsevier Inc. All rights reserved.
– notice: Crown Copyright © 2020 Published by Elsevier Inc. All rights reserved. 2020
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
5PM
DOI 10.1016/j.sapharm.2020.05.025
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
DatabaseTitleList MEDLINE


Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1934-8150
EndPage 1945
ExternalDocumentID 10_1016_j_sapharm_2020_05_025
32499161
S1551741120306021
Genre Journal Article
GeographicLocations Canada
GeographicLocations_xml – name: Canada
GroupedDBID ---
--K
--M
.~1
0R~
123
1B1
1CY
1~.
1~5
4.4
457
4G.
53G
5VS
7-5
71M
8P~
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AATCM
AAWTL
AAXUO
ABIVO
ABLVK
ABMAC
ABMZM
ABXDB
ABYKQ
ABZDS
ACDAQ
ACGFS
ACHQT
ACRLP
ADBBV
ADEZE
ADMUD
AEBSH
AEKER
AFKWA
AFTJW
AFXIZ
AGHFR
AGUBO
AGYEJ
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
AJRQY
ALCLG
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ANZVX
AXJTR
BKOJK
BLXMC
BNPGV
C45
CS3
DU5
EBS
EFJIC
EFLBG
EJD
EO9
EP2
EP3
F5P
FDB
FEDTE
FIRID
FNPLU
FYGXN
G-Q
GBLVA
HVGLF
HZ~
IHE
J1W
KOM
LCYCR
M41
MO0
N9A
O-L
O9-
OAUVE
OGGZJ
OVD
OZT
P-8
P-9
P2P
PC.
Q38
RIG
ROL
RPZ
SDF
SDG
SEL
SES
SPCBC
SSH
SSP
SSZ
T5K
TEORI
~G-
AAXKI
AFJKZ
AKRWK
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
ACRPL
ADNMO
CITATION
5PM
ID FETCH-LOGICAL-c467t-b1796313ccf639f03c186ee2452be924c335ae02dec10683aba2c4517d3b92ef3
IEDL.DBID .~1
ISSN 1551-7411
IngestDate Tue Sep 17 21:06:33 EDT 2024
Fri Dec 06 03:38:52 EST 2024
Sat Nov 02 12:01:02 EDT 2024
Fri Feb 23 02:47:06 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords COVID-19
Virtual care
Elderly population
Deprescribing
Drug safety
Language English
License Crown Copyright © 2020. Published by Elsevier Inc. All rights reserved.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c467t-b1796313ccf639f03c186ee2452be924c335ae02dec10683aba2c4517d3b92ef3
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC7256521
PMID 32499161
PageCount 4
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_7256521
crossref_primary_10_1016_j_sapharm_2020_05_025
pubmed_primary_32499161
elsevier_sciencedirect_doi_10_1016_j_sapharm_2020_05_025
PublicationCentury 2000
PublicationDate 2021-01-01
PublicationDateYYYYMMDD 2021-01-01
PublicationDate_xml – month: 01
  year: 2021
  text: 2021-01-01
  day: 01
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Research in social and administrative pharmacy
PublicationTitleAlternate Res Social Adm Pharm
PublicationYear 2021
Publisher Elsevier Inc
Published by Elsevier Inc
Publisher_xml – name: Elsevier Inc
– name: Published by Elsevier Inc
References Bulut, Kato (bib7) 2020; 50
(bib19) 2020
Trenaman, Willison, Robinson, Andrew (bib16) 2019; 16
Szperling (bib26) 2020
(bib25) 2018
Abu Fadaleh, Shkrobot, Makhinova, Eurich, Sadowski (bib4) 2020
bib10
Kalogianis, Wimmer, Turner (bib15) 2016; 12
Gillespie, Harrison, Mullan (bib13) 2018; 1
Sirois, Ouellet, Reeve (bib14) 2017; 13
(bib24) 2020
Farrell, Richardson, Raman-Wilms, de Launay, Alsabbagh, Conklin (bib23) 2018; 14
D'Avanzo, Agosti, Reeve (bib17) 2020; 134
Djatche, Lee, Singer, Hegarty, Lombardi, Maio (bib18) 2018; 43
Kuntz (bib11) 2018; 22
Zechmann, Trueb, Valeri, Streit, Senn, Neuner-Jehle (bib12) 2019; 20
Dharmarajan, Choi, Hossain (bib9) 2020
Page, Potter, Clifford, Etherton-Beer (bib3) 2016
Rothan, Byrareddy (bib6) 2020; 109
Conklin, Farrell, Suleman (bib20) 2019; 15
(bib2) 2020
bib5
(bib8) 2016
Moriarity, Pottie, Dolovih, McCarthy (bib21) 2019; 15
bib1
Bredhold, Deodhar, Davis, DiRenzo, Isaacs, Campbell (bib22) 2020
33288419 - Res Social Adm Pharm. 2021 May;17(5):1024-1025
Conklin (10.1016/j.sapharm.2020.05.025_bib20) 2019; 15
Sirois (10.1016/j.sapharm.2020.05.025_bib14) 2017; 13
Bulut (10.1016/j.sapharm.2020.05.025_bib7) 2020; 50
D'Avanzo (10.1016/j.sapharm.2020.05.025_bib17) 2020; 134
Moriarity (10.1016/j.sapharm.2020.05.025_bib21) 2019; 15
Page (10.1016/j.sapharm.2020.05.025_bib3) 2016
Rothan (10.1016/j.sapharm.2020.05.025_bib6) 2020; 109
(10.1016/j.sapharm.2020.05.025_bib8) 2016
Abu Fadaleh (10.1016/j.sapharm.2020.05.025_bib4) 2020
Kuntz (10.1016/j.sapharm.2020.05.025_bib11) 2018; 22
Djatche (10.1016/j.sapharm.2020.05.025_bib18) 2018; 43
Kalogianis (10.1016/j.sapharm.2020.05.025_bib15) 2016; 12
Dharmarajan (10.1016/j.sapharm.2020.05.025_bib9) 2020
(10.1016/j.sapharm.2020.05.025_bib19) 2020
Farrell (10.1016/j.sapharm.2020.05.025_bib23) 2018; 14
Zechmann (10.1016/j.sapharm.2020.05.025_bib12) 2019; 20
Bredhold (10.1016/j.sapharm.2020.05.025_bib22) 2020
Szperling (10.1016/j.sapharm.2020.05.025_bib26)
Gillespie (10.1016/j.sapharm.2020.05.025_bib13) 2018; 1
Trenaman (10.1016/j.sapharm.2020.05.025_bib16) 2019; 16
References_xml – ident: bib10
  article-title: Deprescribing initiatives in Canada
– volume: 12
  start-page: 784
  year: 2016
  end-page: 788
  ident: bib15
  article-title: Are residents of aged care facilities willing to have their medications deprescribed?
  publication-title: Res Soc Adm Pharm
  contributor:
    fullname: Turner
– volume: 134
  start-page: 29
  year: 2020
  end-page: 33
  ident: bib17
  article-title: Views of medical practitioners about deprescribing in older adults: findings from an Italian qualitative study
  publication-title: Maturitas
  contributor:
    fullname: Reeve
– volume: 22
  start-page: 17
  year: 2018
  end-page: 157
  ident: bib11
  article-title: Barriers and facilitators to the deprescribing of nonbenzodiazepine sedative medications among older adults
  publication-title: Perm J
  contributor:
    fullname: Kuntz
– volume: 20
  start-page: 64
  year: 2019
  ident: bib12
  article-title: Barriers and enablers for deprescribing among older, multimorbid patients with polypharmacy: an explorative study from Switzerland
  publication-title: BMC Fam Pract
  contributor:
    fullname: Neuner-Jehle
– volume: 109
  year: 2020
  ident: bib6
  article-title: The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak
  publication-title: J Autoimmun
  contributor:
    fullname: Byrareddy
– year: 2016
  ident: bib3
  article-title: Deprescribing in Older People
  contributor:
    fullname: Etherton-Beer
– volume: 13
  start-page: 864
  year: 2017
  end-page: 870
  ident: bib14
  article-title: Community-dwelling older people's attitudes towards deprescribing in Canada
  publication-title: Res Soc Adm Pharm
  contributor:
    fullname: Reeve
– year: 2016
  ident: bib8
  publication-title: Drug Use Among Seniors in Canada
– volume: 16
  start-page: 595
  year: 2019
  end-page: 598
  ident: bib16
  article-title: A collaborative intervention for deprescribing: the role of stakeholder and patient engagement
  publication-title: Res Soc Adm Pharm
  contributor:
    fullname: Andrew
– volume: 43
  start-page: 550
  year: 2018
  end-page: 555
  ident: bib18
  article-title: How confident are physicians in deprescribing for the elderly and what barriers prevent deprescribing?
  publication-title: J Clin Pharm Therapeut
  contributor:
    fullname: Maio
– year: 2020
  ident: bib26
  article-title: Ottawa non-profit organization helps seniors connect during COVID pandemic
  contributor:
    fullname: Szperling
– volume: 15
  year: 2019
  ident: bib20
  article-title: Implementing deprescribing guidelines into frontline practice: barriers and facilitators
  publication-title: Res Soc Adm Pharm
  contributor:
    fullname: Suleman
– volume: 14
  start-page: 18
  year: 2018
  end-page: 25
  ident: bib23
  article-title: Self-efficacy for deprescribing: a survey for health care professionals using evidence-based deprescribing guidelines
  publication-title: Res Soc Adm Pharm
  contributor:
    fullname: Conklin
– year: 2020
  ident: bib2
  article-title: What is deprescribing? — do I still need this medication? Is deprescribing for you?
– start-page: 355
  year: 2020
  end-page: 360
  ident: bib9
  article-title: Deprescribing as a clinical improvement focus
  publication-title: J Am Med Dir Assoc
  contributor:
    fullname: Hossain
– year: 2020
  ident: bib19
  publication-title: Progress in Canada
– year: 2020
  ident: bib24
  article-title: Rapid response to COVID-19
– volume: 50
  start-page: 563
  year: 2020
  end-page: 566
  ident: bib7
  article-title: Epidemiology of COVID-19
  publication-title: Turk J Med Sci
  contributor:
    fullname: Kato
– year: 2018
  ident: bib25
  article-title: Living arrangements of seniors
– year: 2020
  ident: bib22
  article-title: Deprescribing opportunities for elderly inpatients in an academic, safety-net health system
  publication-title: Res Soc Adm Pharm
  contributor:
    fullname: Campbell
– volume: 15
  start-page: 806
  year: 2019
  end-page: 810
  ident: bib21
  article-title: Deprescribing recommendations: an essential consideration for clinical guidelines developers
  publication-title: Res Soc Adm Pharm
  contributor:
    fullname: McCarthy
– ident: bib5
  article-title: Q&A on coronaviruses (COVID-19)
– year: 2020
  ident: bib4
  article-title: Financial advantage or barrier when deprescribing for seniors: a case based analysis
  publication-title: Res Soc Adm Pharm
  contributor:
    fullname: Sadowski
– ident: bib1
  article-title: Deprescribing: managing medications to reduce polypharmacy
– volume: 1
  start-page: e45
  year: 2018
  ident: bib13
  article-title: Deprescribing medications for older adults in the primary care context: a mixed studies review
  publication-title: Health Sci Rep
  contributor:
    fullname: Mullan
– volume: 109
  year: 2020
  ident: 10.1016/j.sapharm.2020.05.025_bib6
  article-title: The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak
  publication-title: J Autoimmun
  doi: 10.1016/j.jaut.2020.102433
  contributor:
    fullname: Rothan
– year: 2020
  ident: 10.1016/j.sapharm.2020.05.025_bib19
– ident: 10.1016/j.sapharm.2020.05.025_bib26
  contributor:
    fullname: Szperling
– volume: 16
  start-page: 595
  issue: 4
  year: 2019
  ident: 10.1016/j.sapharm.2020.05.025_bib16
  article-title: A collaborative intervention for deprescribing: the role of stakeholder and patient engagement
  publication-title: Res Soc Adm Pharm
  doi: 10.1016/j.sapharm.2019.07.004
  contributor:
    fullname: Trenaman
– volume: 12
  start-page: 784
  issue: 5
  year: 2016
  ident: 10.1016/j.sapharm.2020.05.025_bib15
  article-title: Are residents of aged care facilities willing to have their medications deprescribed?
  publication-title: Res Soc Adm Pharm
  doi: 10.1016/j.sapharm.2015.12.004
  contributor:
    fullname: Kalogianis
– volume: 22
  start-page: 17
  year: 2018
  ident: 10.1016/j.sapharm.2020.05.025_bib11
  article-title: Barriers and facilitators to the deprescribing of nonbenzodiazepine sedative medications among older adults
  publication-title: Perm J
  doi: 10.7812/TPP/17-157
  contributor:
    fullname: Kuntz
– volume: 20
  start-page: 64
  issue: 1
  year: 2019
  ident: 10.1016/j.sapharm.2020.05.025_bib12
  article-title: Barriers and enablers for deprescribing among older, multimorbid patients with polypharmacy: an explorative study from Switzerland
  publication-title: BMC Fam Pract
  doi: 10.1186/s12875-019-0953-4
  contributor:
    fullname: Zechmann
– year: 2016
  ident: 10.1016/j.sapharm.2020.05.025_bib3
  contributor:
    fullname: Page
– volume: 1
  start-page: e45
  issue: 7
  year: 2018
  ident: 10.1016/j.sapharm.2020.05.025_bib13
  article-title: Deprescribing medications for older adults in the primary care context: a mixed studies review
  publication-title: Health Sci Rep
  doi: 10.1002/hsr2.45
  contributor:
    fullname: Gillespie
– start-page: 355
  year: 2020
  ident: 10.1016/j.sapharm.2020.05.025_bib9
  article-title: Deprescribing as a clinical improvement focus
  publication-title: J Am Med Dir Assoc
  doi: 10.1016/j.jamda.2019.08.031
  contributor:
    fullname: Dharmarajan
– volume: 15
  issue: 6
  year: 2019
  ident: 10.1016/j.sapharm.2020.05.025_bib20
  article-title: Implementing deprescribing guidelines into frontline practice: barriers and facilitators
  publication-title: Res Soc Adm Pharm
  doi: 10.1016/j.sapharm.2018.08.012
  contributor:
    fullname: Conklin
– volume: 43
  start-page: 550
  issue: 4
  year: 2018
  ident: 10.1016/j.sapharm.2020.05.025_bib18
  article-title: How confident are physicians in deprescribing for the elderly and what barriers prevent deprescribing?
  publication-title: J Clin Pharm Therapeut
  doi: 10.1111/jcpt.12688
  contributor:
    fullname: Djatche
– year: 2020
  ident: 10.1016/j.sapharm.2020.05.025_bib4
  article-title: Financial advantage or barrier when deprescribing for seniors: a case based analysis
  publication-title: Res Soc Adm Pharm
  doi: 10.1016/j.sapharm.2020.03.003
  contributor:
    fullname: Abu Fadaleh
– volume: 15
  start-page: 806
  issue: 6
  year: 2019
  ident: 10.1016/j.sapharm.2020.05.025_bib21
  article-title: Deprescribing recommendations: an essential consideration for clinical guidelines developers
  publication-title: Res Soc Adm Pharm
  doi: 10.1016/j.sapharm.2018.08.014
  contributor:
    fullname: Moriarity
– year: 2016
  ident: 10.1016/j.sapharm.2020.05.025_bib8
– volume: 14
  start-page: 18
  issue: 1
  year: 2018
  ident: 10.1016/j.sapharm.2020.05.025_bib23
  article-title: Self-efficacy for deprescribing: a survey for health care professionals using evidence-based deprescribing guidelines
  publication-title: Res Soc Adm Pharm
  doi: 10.1016/j.sapharm.2017.01.003
  contributor:
    fullname: Farrell
– volume: 13
  start-page: 864
  issue: 4
  year: 2017
  ident: 10.1016/j.sapharm.2020.05.025_bib14
  article-title: Community-dwelling older people's attitudes towards deprescribing in Canada
  publication-title: Res Soc Adm Pharm
  doi: 10.1016/j.sapharm.2016.08.006
  contributor:
    fullname: Sirois
– volume: 134
  start-page: 29
  year: 2020
  ident: 10.1016/j.sapharm.2020.05.025_bib17
  article-title: Views of medical practitioners about deprescribing in older adults: findings from an Italian qualitative study
  publication-title: Maturitas
  doi: 10.1016/j.maturitas.2020.01.009
  contributor:
    fullname: D'Avanzo
– volume: 50
  start-page: 563
  issue: 3
  year: 2020
  ident: 10.1016/j.sapharm.2020.05.025_bib7
  article-title: Epidemiology of COVID-19
  publication-title: Turk J Med Sci
  doi: 10.3906/sag-2004-172
  contributor:
    fullname: Bulut
– year: 2020
  ident: 10.1016/j.sapharm.2020.05.025_bib22
  article-title: Deprescribing opportunities for elderly inpatients in an academic, safety-net health system
  publication-title: Res Soc Adm Pharm
  doi: 10.1016/j.sapharm.2020.04.029
  contributor:
    fullname: Bredhold
SSID ssj0037014
Score 2.3724768
Snippet Deprescribing aims to reduce polypharmacy, especially in the elderly population, in order to maintain or improve quality of life, reduce harm from medications,...
SourceID pubmedcentral
crossref
pubmed
elsevier
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 1942
SubjectTerms Aged
Canada
Computer Literacy
COVID-19
COVID-19 - prevention & control
COVID-19 - transmission
Delivery of Health Care - economics
Delivery of Health Care - organization & administration
Deprescribing
Deprescriptions
Drug safety
Drug-Related Side Effects and Adverse Reactions - prevention & control
Elderly population
Electronic Health Records
Health Care Costs
Health Services Accessibility
Humans
Polypharmacy
Quality of Life
Telemedicine
Virtual care
Title Barriers to conducting deprescribing in the elderly population amid the COVID-19 pandemic
URI https://dx.doi.org/10.1016/j.sapharm.2020.05.025
https://www.ncbi.nlm.nih.gov/pubmed/32499161
https://pubmed.ncbi.nlm.nih.gov/PMC7256521
Volume 17
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07T8MwELaqsrAg3pRH5QExkTaJnUfHUqjKQ1BBQTBFtuOIVBCitgxd-O3cOWlLp0pMUWJHse6cu-_s83eEnDIheMJ4y1KAPXCbkVtSisDytasTHrrSVybb4t7vPfObV--1QjqzszCYVlna_sKmG2tdPmmW0mzmadp8QmcP_tBxEfba5jA592ysYtD4mad5sMA2_N7Y2cLei1M8zWFjLHIkiIYw0bUNgSdWzF7hn5ZzJ_84o-4m2ShRJG0XA90iFZ1tk7N-QUM9PaeDxamq8Tk9o_0FQfV0h7xdiBEWqhvTyReFeBgpX8GD0SIrFsyIxLs0owAOqcYy3h9Tms8rfVHxmcamrfPwcn1pOS2a41L0Z6p2yXP3atDpWWWJBUuBhZxYEv5HnzlMqQSgSmIz5YS-1rgdKzWEZooxT2jbjbWC2DFkQgpXcZB7zGQLtMn2SDX7yvQBoSEXfgxg0fV1wG2uAQh7IolbIXNi5FmrkcZMsFFeMGlEsxSzYVRqIkJNRLYXgSZqJJyJP1qaEhFY-1Wv7hdamn8JcCMiYadGgiX9zTsgzfZyS5a-G7rtAFAhgJzD_w_niKy7mApjVm6OSXUy-tYngGUmsm4ma52stTuPd328Xt_27n8BIfn2zA
link.rule.ids 230,314,780,784,885,4502,24116,27924,27925,45585,45679
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07T8MwELYQDLAg3pSnB9SpaZPYeXSEAipQoBIFwWTZjiNSQYjaMnTht3OXpC2dKjEmdpTozrn7zr77jpAzJiWPGW9aGrAHHjNySykZWL5xTcxDV_k6z7Z48NvP_PbVe10irUktDKZVlra_sOm5tS7vNEppNrIkaTyhswd_6LgIe20sJl_hHqBfWNT1n2meBwvsnOAbZ1s4fVbG0-jXhzJDhmiIE107Z_DEltkLHNR88uQfb3S9QdZLGEnPiy_dJEsm3SLVbsFDPa7R3qysalijVdqdMVSPt8nbhRxgp7ohHX1RCIiR8xVcGC3SYsGOKLxKUgrokBrs4_0xptm01ReVn0mUj7UeX24uLadJM9yL_kz0Dnm-vuq12lbZY8HSYCJHloIf0mcO0zoGrBLbTDuhbwyexyoDsZlmzJPGdiOjIXgMmVTS1RwEHzHVBHWyXbKcfqVmn9CQSz8CtOj6JuA2N4CEPRlHzZA5ERKtVUh9IliRFVQaYpJj1helJgRqQtieAE1USDgRv5hbEwLM_aJH9wotTd8EwBGhsFMhwZz-phOQZ3t-JE3ec77tAGAhoJyD_3_OKVlt9-47onPzcHdI1lzMi8m3cY7I8mjwbY4B2IzUSb5wfwEz9_bU
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Barriers+to+conducting+deprescribing+in+the+elderly+population+amid+the+COVID-19+pandemic&rft.jtitle=Research+in+social+and+administrative+pharmacy&rft.au=Elbeddini%2C+Ali&rft.au=Prabaharan%2C+Thulasika&rft.au=Almasalkhi%2C+Sarah&rft.au=Tran%2C+Cindy&rft.date=2021-01-01&rft.issn=1551-7411&rft.volume=17&rft.issue=1&rft.spage=1942&rft.epage=1945&rft_id=info:doi/10.1016%2Fj.sapharm.2020.05.025&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_sapharm_2020_05_025
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1551-7411&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1551-7411&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1551-7411&client=summon